MSP Recovery Inc. Secures $2.9 Million in Settlements Amid Ongoing Litigation with Insurer and Pharmaceutical Company
Reuters
Sep 23
MSP Recovery Inc. Secures $2.9 Million in Settlements Amid Ongoing Litigation with Insurer and Pharmaceutical Company
MSP Recovery Inc. has reached a series of confidential settlements totaling $2.9 million in cash. The settlements involve a mediated agreement with a property and casualty insurer and a resolution with a pharmaceutical defendant. The agreement with the insurer includes provisions for sharing historical data and resolving Medicare claims through cooperative means or binding mediation. Meanwhile, the pharmaceutical settlement addresses allegations of overpayments linked to a prescription drug scheme. These settlements are expected to impact the company's management of current and future Medicare claims.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MSP Recovery Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-209312), on September 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.